Galvanize Secures $100M Series C and Appoints Doug Godshall as CEO to Advance PEF Therapies

Redwood City, CA, September 3, 2025 (PRNewswire) -- Galvanize Therapeutics closed an oversubscribed $100 million Series C round led by Sofinnova Partners to develop its pulsed electric field (PEF) platform targeting solid tumors and chronic bronchitis. The funding will expand commercial operations and advance clinical programs for Aliya® PEF and RheOx® therapies. Doug Godshall was appointed CEO and Chairman, with Jonathan Waldstreicher becoming President and Chief Strategy Officer, marking a new leadership phase for the company.

Read full article here.